Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15477906 | 1.00 | S1PR1 (0.44) | S1PR1S1PR3S1PR4S1PR5TTR | |
| SCHEMBL16920506 | 0.82 | KDM4E (0.56) | CYP1A2KDM4E | |
| SCHEMBL28437357 | 0.81 | FDPS (0.63) | ALDH1A1CYP1A2NPSR1KDM4ELMNA | |
| SCHEMBL23909065 | 0.80 | ALDH1A1 (0.47) | S1PR4TTRALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL3725582 | 0.80 | ALDH1A1 (0.47) | TTRALDH1A1CYP1A2CYP2D6LMNA | |
| SCHEMBL10432959 | 0.80 | CYP1A2 (0.62) | S1PR4ALDH1A1CYP1A2CYP2D6NPSR1 | |
| SCHEMBL5703181 | 0.78 | ALDH1A1 (0.44) | TTRALDH1A1CYP1A2CYP2D6LMNA | |
| SCHEMBL12677544 | 0.77 | NPSR1 (0.68) | ALDH1A1CYP1A2CYP2D6NPSR1KDM4E | |
| SCHEMBL15477953 | 0.77 | ALDH1A1 (0.47) | TTRALDH1A1CYP1A2CYP2D6LMNA | |
| SCHEMBL15565588 | 0.77 | ALDH1A1 (0.49) | S1PR4TTRALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2885266-B1 | PROCESS FOR THE PREPARATION OF (2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-18 | — | — | EP | claimed |
| US-9340518-B2 | Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-17 | — | — | US | claimed |
| US-20150203459-A1 | PROCESS FOR THE PREPARATION OF [(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-](O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2015-07-23 | — | — | US | claimed |
| EP-2885266-A1 | PROCESS FOR THE PREPARATION OF!(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-!(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | Actelion Pharmaceuticals Ltd. (CH) | 2015-06-24 | — | — | EP | claimed |
| WO-2014027330-A1 | PROCESS FOR THE PREPARATION OF|(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-|(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-02-20 | — | — | WO | claimed |
| WO-2023152691-A1 | PROCESS FOR THE PREPARATION OF PONESIMOD AND ITS INTERMEDIATES THEREOF | METROCHEM API PVT LTD (IN) | 2023-08-17 | — | — | WO | disclosed |
| EP-2885266-B1 | PROCESS FOR THE PREPARATION OF (2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-03-18 | — | — | EP | disclosed |
| CN-104540800-B | Process for the preparation of (2Z,5Z)-5-(3-chloro-4- ((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | 埃科特莱茵药品有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9340518-B2 | Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9340518-B2 | Process for the preparation of (2Z,5Z)-5-(3-chloro-4-((R)-2,3-dihydroxypropdxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20150203459-A1 | PROCESS FOR THE PREPARATION OF [(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-](O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2015-07-23 | — | — | US | disclosed |
| US-20150203459-A1 | PROCESS FOR THE PREPARATION OF [(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-](O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2015-07-23 | — | — | US | disclosed |
| US-7626037-B2 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20090275625-A1 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080280962-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
| US-7435828-B2 | immunosuppressive agents; low dosages; 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20080146629-A1 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
| EP-1689726-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054215-A1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | TLR4, IL4, IRF3 | S1PR1 2472/4885S1PR3 2136/4885S1PR4 978/4885 |
| US-20090275625-A1 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES | TLR4, IRF3, TLR1 | S1PR1 2446/4885S1PR3 2137/4885S1PR4 1247/4885 |
| US-20080146629-A1 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ICOS, IL2, IKZF3 | S1PR1 1684/4885S1PR3 1293/4885S1PR4 836/4885 |
| US-20080280962-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | TLR4, IL4, IRF3 | S1PR1 2472/4885S1PR3 2136/4885S1PR4 978/4885 |
| US-20150203459-A1 | PROCESS FOR THE PREPARATION OF [(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-](O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS | IL15, IL15RA, IL5 | S1PR1 2469/4885S1PR3 1495/4885S1PR4 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.